Skip to content

Can we improve the management of Juvenile PsA patients by using a different disease activity measure?

Can we improve the management of Juvenile PsA patients by using a different disease activity measure? - Key disease activity markers in Juvenile PsA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51719
Enrollment
100
Registered
2022-04-29
Start date
2022-05-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

juvenile arthritis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
12 Years to 64 Years

Inclusion criteria

Inclusion criteria: patients of the outpatient department of the Erasmus MC diagnosed with possible Juvenile PsA including the subtypes: - Juvenile PsA, - Oligoarticular JIA, - Polyarticular rheumatoid factor negative JIA - Enthesitis related JIA - Undifferentiated JIA - Age between the ages of 12 and 24 - Patients must be able to understand and communicate with the Investigator and comply with the requirements of the study - Patients and/or legal guardian must give a written, signed and dated informed consent before any study assessment is performed.

Exclusion criteria

Exclusion criteria: - not willing to participate - uncapable of understanding Dutch language

Design outcomes

Primary

MeasureTime frame
MDA-JADAS JADAS adds the active joint count (selection of 27 joints out of total of 71 joints), vas global physician, vas global child and ESR together in a total score. The cutoff for classification of minimal disease activity is 2 for oligoarticular JIA and 3.8 for polyarticular JIA, (25) MDA-PsA The subjects achieving minimal disease activity (MDA), is defined as 5 of the following 7 domains:

Secondary

MeasureTime frame
Disease burden, functioning, quality of life and participation in society, as experienced by the patient, evaluated by means of PROMs.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)